BRUSSELS, June 1, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company, is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism

ATLANTA, May 18, 2012 /PRNewswire/ -- UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological

ATLANTA, April 26, 2012 /PRNewswire/ -- Insights into the effects of Neupro(®) (rotigotine transdermal system) on common non-motor symptoms of Parkinson's disease (PD) were

ATLANTA, April 20, 2012 /PRNewswire/ -- Data examining the effect of Neupro® (rotigotine transdermal system) in both Parkinson's disease and Restless Legs Syndrome (RLS) will

ATLANTA, April 20, 2012 /PRNewswire/ -- To help people learn more about the full range of symptoms associated with Parkinson's disease, global biopharmaceutical company UCB, Inc., is launching